Clinical Trial

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This randomized phase III trial studies how well cisplatin or carboplatin (platinum based chemotherapy) works compared to capecitabine in treating patients with remaining (residual) basal-like triple-negative breast cancer following chemotherapy after surgery (neoadjuvant). Drugs used in chemotherapy, such as cisplatin, carboplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether cisplatin or carboplatin is more effective than capecitabine in treating patients with residual triple negative basal-like breast cancer.
Protocol Amendment History 20 amendments
This ClinicalTrials.gov record has been amended 20 times since 2015-05-14; most recent amendment 2026-07-09.
Status change: Recruiting → Active, Not Recruiting 2022-09-07
Trial Details
NCT Number NCT02445391
Lead Sponsor ECOG-ACRIN Cancer Research Group
Collaborators: National Cancer Institute (NCI)
Conditions Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer +4 more
Enrollment 415 participants
Start Date 2015-10-20
Primary Completion 2021-04-07 (estimated)
Study Completion 2031-03-29 (estimated)
Updated on ClinicalTrials.gov 2026-07-27